The novel apolipoprotein A5 is present in human serum, is associated with VLDL, HDL, and chylomicrons, and circulates at very low concentrations compared with other apolipoproteins
about
Effects of apoA-V on HDL and VLDL metabolism in APOC3 transgenic miceShotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDLGenetics of lipid traits and relationship to coronary artery diseaseProteomics investigations of HDL: challenges and promiseImpact of apolipoprotein A5 variants on statin treatment efficacyApolipoprotein A-V dependent modulation of plasma triacylglycerol: a puzzlementApolipoprotein A5 and triglyceridemia. Focus on the effects of the common variantsThe paradox of ApoA5 modulation of triglycerides: evidence from clinical and basic researchInfluence of apolipoprotein A-V on the metabolic fate of triacylglycerolAPOA5 Ala315>Val, identified in patients with severe hypertriglyceridemia, is a common mutation with no major effects on plasma lipid levelsClinical significance of apolipoprotein A5Is apolipoprotein A5 a novel regulator of triglyceride-rich lipoproteins?Hepatitis B virus inhibits apolipoprotein A5 expression through its core geneA bivariate genome-wide approach to metabolic syndrome: STAMPEED consortiumThe C terminus of apolipoprotein A-V modulates lipid-binding activity.Increased concentrations of circulating vitamin E in carriers of the apolipoprotein A5 gene - 1131T>C variant and associations with plasma lipids and lipid peroxidation.Localized-statistical quantification of human serum proteome associated with type 2 diabetesAssociation of two common polymorphisms of apolipoprotein A5 gene with metabolic syndrome indicators in a North Iranian population, a cross-sectional study.Interactions of the apolipoprotein A5 gene polymorphisms and alcohol consumption on serum lipid levels.The N-terminus of apolipoprotein A-V adopts a helix bundle molecular architecture.The expression of type III hyperlipoproteinemia: involvement of lipolysis genesIntravenous injection of apolipoprotein A-V reconstituted high-density lipoprotein decreases hypertriglyceridemia in apoav-/- mice and requires glycosylphosphatidylinositol-anchored high-density lipoprotein-binding protein 1.APOA5 Q97X mutation identified through homozygosity mapping causes severe hypertriglyceridemia in a Chilean consanguineous family.Genetic determinants of plasma triglyceridesAssociation of a genetic variant of the ZPR1 zinc finger gene with type 2 diabetes mellitus.Factors associated with postprandial lipemia and apolipoprotein A-V levels in individuals with familial combined hyperlipidemiaApolipoprotein A1/C3/A5 haplotypes and serum lipid levelsApolipoprotein A-V deficiency enhances chylomicron production in lymph fistula miceAssociation of apolipoprotein A5 concentration with serum insulin and triglyceride levels and coronary artery disease in Korean men.Increased apolipoprotein A5 expression in human and rat non-alcoholic fatty livers.Association of FURIN and ZPR1 polymorphisms with metabolic syndrome.Interaction of dietary fat intake with APOA2, APOA5 and LEPR polymorphisms and its relationship with obesity and dyslipidemia in young subjects.Give me A5 for lipoprotein hydrolysis!Influence of apolipoprotein A-V on hepatocyte lipid droplet formationDeterminants of plasma apolipoprotein A-V and APOA5 gene transcripts in humans.Lipoprotein metabolism in nonalcoholic fatty liver diseaseStructural and functional analysis of APOA5 mutations identified in patients with severe hypertriglyceridemia.Intracellular lipid droplet targeting by apolipoprotein A-V requires the carboxyl-terminal segmentGrape Seed Procyanidins and Cholestyramine Differentially Alter Bile Acid and Cholesterol Homeostatic Gene Expression in Mouse Intestine and Liver.Gene transfer of apolipoprotein A-V improves the hypertriglyceridemic phenotype of apoa5 (-/-) mice.
P2860
Q24302828-B250F9C1-CECB-4AF0-A6A0-9B891A66197BQ24669594-763EF499-7F0D-42D7-B11E-6A62B44DA38FQ26995252-D4C5FC43-F349-45DE-9AA4-C44C2977AAAEQ27000995-2947A011-0834-4D68-AA61-34D7545171F5Q28248690-2472A215-D74C-480A-A911-160A180E512DQ28256394-703D8618-2B16-4EC9-929D-4F5779C4C7C3Q28273374-928C3078-E68D-438D-84A3-59EAAFD21601Q28275573-902079F0-3B24-4957-A90F-1CF48A6ACE0DQ28281468-FEC2BF1F-E856-441B-A724-048BC4010C4FQ28286099-3E57261F-D3B4-4473-B6FA-56C0BE2B071AQ28286349-FBA340B7-26E4-4863-9556-55EDD5A7D089Q28294769-457EE403-6C2B-4171-8203-9E7F9487D27EQ28597775-4D1F2128-4F64-4E7D-93E6-68B4E550F5D2Q28943346-9481FA46-D229-425B-8508-37D6134B480BQ30360807-45B7BFBF-F001-4F7B-BF51-CBB00C1608E6Q33293923-A7E08551-601B-443B-8A34-BC2A89382050Q33369848-AE169FFB-830E-407F-9F70-E714DC65B5C6Q33649101-44F50716-CF52-4156-AC95-032C131E1A37Q33851689-34503787-C366-41DB-A1B6-ED1101DCA87AQ33946941-A759AC36-B558-435F-B4B1-91A1E2A15449Q34326186-A6C72ED1-6F26-4A6B-A3C3-0E1392256001Q34332478-790B6DF1-4557-4C57-A53A-123E41987BCAQ34476810-0958F6BC-4E95-4278-A627-3F5FE48A8BB8Q34503333-552AD98B-9D24-43A3-8287-69A0A173C9A3Q34607502-E51C1C2C-E8F0-49F9-9263-549D94B61627Q34622240-A512D5DC-AB82-4820-9EBD-548751AF6739Q35206176-E9049CEA-9483-42A0-8919-07DD627EB2DAQ35274124-7CE78CC5-45B9-4A77-AD77-DD9B25ED72C6Q35591965-760C8DC3-0792-4BD1-8C34-653BB092D878Q35592272-A6811A03-D7B9-48C8-B338-F9C8B98CDE40Q35948075-F16F8B82-276A-4165-9053-3918D65FDD92Q36054819-C012995E-D26B-4F26-9D3A-1C5B8B2A24C5Q36274976-CD3BA069-F500-4264-BFF4-AFD775330CB7Q36382853-BB9B7C64-B047-4590-8682-83EA15368F0CQ36496770-6CD6F777-B4E1-4E53-A8A5-0E90F4679FB2Q36682138-E10B498E-A172-4E43-A80B-82800BF74C25Q36744086-0AEEDA69-27F7-41C4-ADDC-0E5FF34A4FD7Q36745069-22E7D33E-F740-4ED1-982B-4A83C6EBE70AQ36833239-AAA04680-00CE-4585-93C6-100601FA6C3DQ36856055-4F5EE163-2BC9-4106-BB69-63CDDAA0036A
P2860
The novel apolipoprotein A5 is present in human serum, is associated with VLDL, HDL, and chylomicrons, and circulates at very low concentrations compared with other apolipoproteins
description
2005 nî lūn-bûn
@nan
2005 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
The novel apolipoprotein A5 is ...... red with other apolipoproteins
@ast
The novel apolipoprotein A5 is ...... red with other apolipoproteins
@en
The novel apolipoprotein A5 is ...... red with other apolipoproteins
@en-gb
The novel apolipoprotein A5 is ...... red with other apolipoproteins
@nl
type
label
The novel apolipoprotein A5 is ...... red with other apolipoproteins
@ast
The novel apolipoprotein A5 is ...... red with other apolipoproteins
@en
The novel apolipoprotein A5 is ...... red with other apolipoproteins
@en-gb
The novel apolipoprotein A5 is ...... red with other apolipoproteins
@nl
prefLabel
The novel apolipoprotein A5 is ...... red with other apolipoproteins
@ast
The novel apolipoprotein A5 is ...... red with other apolipoproteins
@en
The novel apolipoprotein A5 is ...... red with other apolipoproteins
@en-gb
The novel apolipoprotein A5 is ...... red with other apolipoproteins
@nl
P2093
P3181
P1433
P1476
The novel apolipoprotein A5 is ...... red with other apolipoproteins
@en
P2093
Albert E Schultze
Amechand Boodhoo
John H Sloan
Maverick Ulmer
Michael D Knierman
Peter J O'Brien
Robert J Konrad
William E Alborn
P3181
P356
10.1373/CLINCHEM.2004.040824
P407
P577
2005-02-01T00:00:00Z